Information regarding a generic version of Glyxambi is not readily available in the provided context. Glyxambi is a prescription medication used to treat type 2 diabetes. It is a combination of two active ingredients: empagliflozin and linagliptin [1].
When is the patent for Glyxambi expected to expire?
Patent expiry dates for medications determine when generic versions can be legally produced and marketed. Information on specific patent expiry dates for Glyxambi is not provided. DrugPatentWatch.com offers resources for tracking patent information for various drugs [2].
What are the active ingredients in Glyxambi?
Glyxambi contains empagliflozin and linagliptin as its active components [1]. Empagliflozin belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors, which help the kidneys remove glucose from the bloodstream. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing levels of incretin hormones, helping to regulate blood sugar [3].
Are there alternative treatments for type 2 diabetes?
Type 2 diabetes can be managed with various treatment approaches, including lifestyle modifications such as diet and exercise, as well as a range of prescription medications. Other classes of drugs used to manage type 2 diabetes include metformin, sulfonylureas, thiazolidinediones, and other DPP-4 inhibitors and SGLT2 inhibitors [4]. Empagliflozin and linagliptin are also available as separate, branded medications [3].
How does Glyxambi work?
Glyxambi works through the combined actions of its two active ingredients. Empagliflozin inhibits SGLT2 in the kidneys, leading to increased urinary glucose excretion and lower blood glucose levels. Linagliptin enhances the effects of incretin hormones, which are released after eating and signal the pancreas to produce more insulin and reduce the liver's production of glucose [3].
Sources:
[1] https://www.glyxambi.com/
[2] https://drugpatentwatch.com/
[3] https://www.mayoclinic.org/drugs-supplements/glyxambi-oral-tablet-combination/about/drg-20074081
[4] https://www.niddk.nih.gov/health-information/diabetes/overview-diabetes/type-2-diabetes